Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Ôîðóìû âðà÷åáíûõ êîíñóëüòàöèé > Ãåìàòîëîãèÿ è òðàíñôóçèîëîãèÿ

Çàêðûòàÿ òåìà
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #16  
Ñòàðûé 25.04.2012, 23:06
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,648
Ïîáëàãîäàðèëè 33,358 ðàç(à) çà 31,703 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
åñëè â äèàãíîçå íåò ñîìíåíèÿ, òî ìàáòåðà ìîæåò áûòü ïðèìåíåíà âìåñòå ñ õèìèîòåðàïèåé ïðè ëå÷åíèè äàííîãî çàáîëåâàíèÿ, ìàáòåðà äîñòóïíà â ÐÔ èëè íà Óêðàèíå, öåíà ïðàâäà âíóøèòåëüíàÿ, ñàìîñòîÿòåëüíî Âû ëå÷åíèå ïðîâåñòè âðÿä ëè ñìîæåòå, òàê ÷òî ê ìàáòåðå âñå ðàâíî íåîáõîäèì î÷íûé ñïåöèàëèñò, êîòîðûé çíàåò êàê ëå÷èòü è âåñòè ïàöèåíòà.
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
  #17  
Ñòàðûé 25.04.2012, 23:15
srochno srochno âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 09.04.2012
Ãîðîä: ...
Ñîîáùåíèé: 61
Ñêàçàë(à) ñïàñèáî: 21
Ïîáëàãîäàðèëè 1 ðàç çà 1 ñîîáùåíèå
srochno *
Öèòàòà:
Ñîîáùåíèå îò Dr.Vad Ïîñìîòðåòü ñîîáùåíèå
åñëè â äèàãíîçå íåò ñîìíåíèÿ, òî ìàáòåðà ìîæåò áûòü ïðèìåíåíà âìåñòå ñ õèìèîòåðàïèåé ïðè ëå÷åíèè äàííîãî çàáîëåâàíèÿ, ìàáòåðà äîñòóïíà â ÐÔ èëè íà Óêðàèíå, öåíà ïðàâäà âíóøèòåëüíàÿ, ñàìîñòîÿòåëüíî Âû ëå÷åíèå ïðîâåñòè âðÿä ëè ñìîæåòå, òàê ÷òî ê ìàáòåðå âñå ðàâíî íåîáõîäèì î÷íûé ñïåöèàëèñò, êîòîðûé çíàåò êàê ëå÷èòü è âåñòè ïàöèåíòà.
Òî åñòü ìàáòåðà + õèìèîòåðàïèÿ âìåñòî îïåðàöèè?

Ìåñòíîãî ñïåöèàëèñòà ïûòàþñü íàéòè, ïûòàþñü...
 ìåñòíûõ àïòåêàõ ìàáòåðû íåò, ïîïðîáóþ ÷åðåç ÐÔ èëè Óêðàèíó...
  #18  
Ñòàðûé 25.04.2012, 23:18
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,648
Ïîáëàãîäàðèëè 33,358 ðàç(à) çà 31,703 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
èíîãäà ïðåïàðàò ìîæåò ââîäèòüñÿ è â âèäå ìîíîòåðàïèè (áåç õèìèîòåðàïèè), ïîäðîáíåå îò èçðàèëüñêèõ ñïåöèàëèñòîâ:

Semin Hematol. 2010 Apr;47(2):143-7.
Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M, Schechter GP.
Department of Hematology, Ha'Emek Medical Center, Afula, Israel.

Splenic marginal zone lymphoma (SMZL) is an uncommon indolent B-cell lymphoma causing marked splenic enlargement with CD20-rich lymphoma cells infiltrating blood and bone marrow. In the pre-rituximab era, the treatment of choice for patients with symptomatic splenomegaly or threatening cytopenia was splenectomy, since chemotherapy had limited efficacy. Responses to splenectomy occurred in approximately 90% of patients. However, SMZL patients are often elderly and poor surgical risks. Since approval of rituximab, treatment of such patients with the anti-CD20 antibody both alone or in combination with chemotherapy has shown remarkable responses. In retrospective series of rituximab monotherapy totaling 52 patients, including both chemotherapy-naive and -refractory patients, overall responses of 88% to 100% were noted with marked and prompt regression of splenomegaly and improvement of cytopenias. Sustained responses occurred both with and without rituximab maintenance in 60% to 88% of patients at 3 years. Relapsed patients responded to second courses of rituximab monotherapy. Overall survival was comparable to that reported following splenectomy. Rituximab in combination with purine nucleosides may provide further improvement in progression-free survival; however, confirmatory prospective trials are necessary. These results suggest that splenectomy should no longer be considered as initial therapy for SMZL but rather as palliative therapy for patients not responsive to immunotherapy with or without chemotherapy.
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
  #19  
Ñòàðûé 26.04.2012, 01:59
anikaa anikaa âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 19.05.2008
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 7,017
Ñêàçàë(à) ñïàñèáî: 22
Ïîáëàãîäàðèëè 2,827 ðàç(à) çà 2,718 ñîîáùåíèé
anikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Áåç ãèñòîëîãèè äèàãíîç ìîæíî òîëüêî ïðåäïîëàãàòü. ×òî íàèáîëåå âåðîÿòíà èìåííî ëèìôîöèòîìà-áûëî î÷åâèäíî ñ ñàìîãî íà÷àëà-ïðîñòî èç âàøèõ ïîñòîâ íå ñëåäîâàëî, ÷òî îáñëåäîâàíèå ïàöèåíòêè çàòÿíåòñÿ äî òàêîé ñòåïåíè ÷òî àäåêâàòíîå ïîäòâåðæäåíèå äèàãíîçà ñòàíåò íåâîçìîæíûì. Õîòü òðåïàí-òî ìîãóò âûïîëíèòü ïåðåä íà÷àëîì òåðàïèè?

Ñåé÷àñ íåò íåîáõîäèìîñòè ñðî÷íî èñêàòü ìàáòåðó. Ïðîâåäèòå áîëüíîé ïðèìèòèâíûé CHOP, åñëè ýòî ïîçâîëÿåò ñîðäå÷íàÿ ôóíêöèÿ(ôðàêöèÿ âûáðîñà?). Åé ñêîðåå âñåãî ðåçêî ïîëåã÷àåò-è äàëüøå áóäåòå 21 äåíü äî ñëåä. êóðñà äóìàòü-õîòèòå òðàòèòü áåøåíûå äåíüãè íà ìàáòåðó èëè íåò. Ñâåò íà íåé êëèíîì íå ñîøåëñÿ. Îíà óëó÷øàåò ïðîãíîç - íî íå ïðèíöèïèàëüíî. Ýòî ïðîñòî î÷åíü ìîäíîå ëåêàðñòâî.
  #20  
Ñòàðûé 26.04.2012, 08:40
srochno srochno âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 09.04.2012
Ãîðîä: ...
Ñîîáùåíèé: 61
Ñêàçàë(à) ñïàñèáî: 21
Ïîáëàãîäàðèëè 1 ðàç çà 1 ñîîáùåíèå
srochno *
Òàê à ÷òî ñ îïåðàöèåé äåëàòü?
Îíà ëåæèò â õèðóðãè÷åñêîì îòäåëåíèè â îíêîëîãè÷åñêîì öåíòðå. Òàì âñå âîêðóã õèðóðãè à íå ãåìàòîëîãè, îíè ðàññìàòðèâàþò îïåðàöèþ êàê åäèíñòâåííóþ îïöèþ. Íàñêîëüêî ÿ ïîíÿë èõ ëîãèêó, îíè õîòÿò ïîäíÿòü åé ãåìîãëîáèí ïåðåëèâàíèÿìè êðîâè è ñäåëàòü îïåðàöèþ äàæå â òàêîì ñîñòîÿíèè êàê îíà ñåé÷àñ, â ïÿòíèöó èëè â ïîíåäåëüíèê. Ïðîñèòü èõ îòëîæèòü îïåðàöèþ?

Äîïîëíèòåëüíûé âîïðîñ: çàïàäíûå ïðîôåññîðà ðåêîìåíäîâàëè äåëàòü âàêöèíàöèþ îò ïíåâìîêîêêà ïåðåä îïåðàöèåé. Òàì ýòî ñòàíäàðòíî. Òóò ýòî íå ïðèíÿòî, è âàêöèíû â ïðèíöèïå â ñòðàíå íåò, íî ÿ çàêàçàë âàêöèíó â Ðîññèè è â ïÿòíèöó ìíå åå íàäåþñü ïðèâåçóò ïîåçäîì. Âîïðîñ: ìîæíî ëè äåëàòü âàêöèíàöèþ âàêöèîíîé Ïðåâåíàð â îñëàáëåííîì ñîñòîÿíèè â ïÿòíèöó, ååñëè îïåðàöèÿ â ïîíåäåëüíèê?
  #21  
Ñòàðûé 26.04.2012, 12:53
anikaa anikaa âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 19.05.2008
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 7,017
Ñêàçàë(à) ñïàñèáî: 22
Ïîáëàãîäàðèëè 2,827 ðàç(à) çà 2,718 ñîîáùåíèé
anikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
×åì çàíèìàòüñÿ âñÿêèìè òðåòüåñòåïåííûìè ïî âàæíîñòè ïðîáëåìàìè òèïà ïðåâåíàðà è êîíñóëüòèðâîàòü ÷åðåç èíòåðíåò- ïåðåâåëè áû ìàìó â ãåìàòîëîãè÷åñêîå ó÷ðåæäåíèå, ÷òî ëè, ðàç ó âàñ ñòîëüêî ýíåðãèè è âñÿêèõ çíàêîìûõ ...
  #22  
Ñòàðûé 26.04.2012, 18:50
srochno srochno âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 09.04.2012
Ãîðîä: ...
Ñîîáùåíèé: 61
Ñêàçàë(à) ñïàñèáî: 21
Ïîáëàãîäàðèëè 1 ðàç çà 1 ñîîáùåíèå
srochno *
Öèòàòà:
Ñîîáùåíèå îò anikaa Ïîñìîòðåòü ñîîáùåíèå
×åì çàíèìàòüñÿ âñÿêèìè òðåòüåñòåïåííûìè ïî âàæíîñòè ïðîáëåìàìè òèïà ïðåâåíàðà è êîíñóëüòèðâîàòü ÷åðåç èíòåðíåò- ïåðåâåëè áû ìàìó â ãåìàòîëîãè÷åñêîå ó÷ðåæäåíèå, ÷òî ëè, ðàç ó âàñ ñòîëüêî ýíåðãèè è âñÿêèõ çíàêîìûõ ...
ïî îôèöèàëüíûì ãîñóäàðñòâåííûì ïðàâèëàì òîé ñòðàíû ÑÍà ãäå ìû íàõîäèìñÿ, ëèìôîìó ëå÷àò â îíêîëîãè÷åñêèõ öåíòðàõ. Ñïåöèàëèçèðîâàííûå ãåìàòîëîãè÷åñêèå îòäåëåíèÿ â äðóãèõ áîëüíèöàõ íå èìåþò ïðàâà îïåðèðîâàòü áîëüíûõ ñ ïîäîçðåíèåì íà îíêîëîãèþ. ß â êîíòàêòå ñ ãåìàòîëîãàìè èç äðóãèõ áîëüíèö - ìû ñíà÷àëà ëåæàëè â äðóãîé áîëüíèöå, è áåç òîëêó, äàæå ãåìàòîëîãè ñàìè ñêàçàëè ïåðåâåñòèñü â îíêîëîãè÷åñêèé öåíòð, ïîòîìó ÷òî â äðóãèõ êëèíèêàõ îíêîëîãèþ íå îïåðèðóþò. Åäèíñòâåííûé âàðèàíò òåïåðü ñìåíèòü êëèíèêó - ýòî âûåõàòü çà ãðàíèöó, íî ýòî â äàííîì ñîñòîÿíèè äîïîëíèòåëüíûé ðèñê èíôèöèðîâàíèÿ ïðè ïåðååçäå, ê òîìó æå äîïîëíèòåëüíàÿ çàäåðæêà ëå÷åíèÿ êàê ìèíèìóì íà íåäåëþ, ïîòîìó ÷òî ëþáàÿ íîâàÿ êëèíèêà çàõî÷åò ïîâòîðèòü âñå àíàëèçû ó ñåáÿ. Âàðèàíò âûåçäà çà ðóáåæ ïî ïðåæíåìó âîçìîæåí. Íî Âû æå ñàìè ïðîòèâ íåãî âîçðàæàëè â ïåðâûõ ïîñòàõ. Ìåíÿåòå ìíåíèå â ïîëüçó ýòîãî âàðèàíòà?
  #23  
Ñòàðûé 26.04.2012, 20:55
anikaa anikaa âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 19.05.2008
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 7,017
Ñêàçàë(à) ñïàñèáî: 22
Ïîáëàãîäàðèëè 2,827 ðàç(à) çà 2,718 ñîîáùåíèé
anikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
ß ìîãó Âàì ñêàçàòü ÷åãî ÍÅ íàäî äåëàòü.
ÍÅ íàäî ïðåïÿòñòâîâàòü ëå÷àùèì âðà÷àì â íà÷àëå òåðàïèè(ëþáîé-õîòÿò è ìîãóò îïåðèðîâàòü-ïóñòü îïåðèðóþò) , â îæèäàíèè ïîêà Âû íàéäåòå ïðåâåíàð, ìàáòåðó è ïðî÷åå íåîáÿçàòåëüíîå.
  #24  
Ñòàðûé 07.05.2012, 23:28
srochno srochno âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 09.04.2012
Ãîðîä: ...
Ñîîáùåíèé: 61
Ñêàçàë(à) ñïàñèáî: 21
Ïîáëàãîäàðèëè 1 ðàç çà 1 ñîîáùåíèå
srochno *
Ñäåëàëè îïåðàöèþ, íåòîðîïëèâî âîññòàíàâëèâàåìñÿ ïîñëå íåå, æäåì ðåçóëüòàòîâ ãèñòîëîãèè. Âîçíèêëè äîïîëíèòåëüíûå âîïðîñû:

Âîïðîñ 1: ïðèìåíÿåòñÿ ëè ìàáòåðà áåç õèìèîòåðàïèè?
Âîïðîñ 2: ñêîëüêî êóðñîâ R-CHOP îáû÷íî ïðîâîäÿò?
Âîïðîñ 3: R-CHOP ëó÷øå äåëàòü ñ ãîñïèòàëèçàöèåé?

Ñïàñèáî!
  #25  
Ñòàðûé 08.05.2012, 01:23
anikaa anikaa âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 19.05.2008
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 7,017
Ñêàçàë(à) ñïàñèáî: 22
Ïîáëàãîäàðèëè 2,827 ðàç(à) çà 2,718 ñîîáùåíèé
anikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
1. äà-íî íå ïðè ëå÷åíèè ëèìôîì.
2. äî äîñòèæåíèÿ ðåìèññèè + 2 êîíñîëèäèðóþùèõ. Èëè äî ðàçâèòèÿ æèçíåóãðîæàþùèõ îñëîæíåíèé. Èëè äî ïðîãðåññèè, òî åñòü ïðè îòñóòñòâèè ýôôåêòà.
3.ïåðâûé êóðñ-åñëè ïîäîçðåâàåòñÿ ðàçùâèòèå òÿæêèõ ñîìàòè÷åñêèå ïîñëåäñòâèé ëèáî åñòü áîëüøîé îáúåì áûñòðîðàñòóùåé îïóõîëè è ñîîòâ.- ðèñê òóìîð-ëèçèñ ñèíäðîìà. Íó èëè ïðè ðåàêöèè íà ââåäåíèå Ìàáòåðû-èíîãäà îêàçûâàåòñÿ íóæíûì ðàñòÿíóòü ââåäåíèå íà 10 è áîëåå ÷àñîâ. Ýòî âñå ðåäêî. Îáû÷íî ãîñïèòàëäèòçàöèÿ íå òðåáóåòñÿ.
  #26  
Ñòàðûé 11.05.2012, 08:16
srochno srochno âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 09.04.2012
Ãîðîä: ...
Ñîîáùåíèé: 61
Ñêàçàë(à) ñïàñèáî: 21
Ïîáëàãîäàðèëè 1 ðàç çà 1 ñîîáùåíèå
srochno *
Öèòàòà:
Ñîîáùåíèå îò Dr.Vad Ïîñìîòðåòü ñîîáùåíèå
In the pre-rituximab era, the treatment of choice for patients with symptomatic splenomegaly or threatening cytopenia was splenectomy, since chemotherapy had limited efficacy. Responses to splenectomy occurred in approximately 90% of patients.
Óâàæàåìûé Dr. Vad,

Âîò ýòà ôðàçà îñîáåííî çàèíòåðåñîâàëà: "Responses to splenectomy occurred in approximately 90% of patients." Îçíà÷àåò ëè ýòî, ÷òî ñïëåíýêòîìèåé â ïðèíöèïå ìîæíî îãðàíè÷èòüñÿ? ×òî îçíà÷àåò â äàííîì êîíòåêñòå "response"? Îçíà÷àåò ëè ýòî, ÷òî ïîñëå ñïëåíýêòîìèè ìîæåò íàñòóïèòü äëèòåëüíàÿ ðåìèññèÿ è õèìèîòåðàïèÿ áóäåò íå íóæíà?
  #27  
Ñòàðûé 11.05.2012, 08:18
srochno srochno âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 09.04.2012
Ãîðîä: ...
Ñîîáùåíèé: 61
Ñêàçàë(à) ñïàñèáî: 21
Ïîáëàãîäàðèëè 1 ðàç çà 1 ñîîáùåíèå
srochno *
Öèòàòà:
Ñîîáùåíèå îò anikaa Ïîñìîòðåòü ñîîáùåíèå
2. äî äîñòèæåíèÿ ðåìèññèè + 2 êîíñîëèäèðóþùèõ.
À êàê îïðåäåëÿåòñÿ ÷òî íàñòóïèëà ðåìèññèÿ?
  #28  
Ñòàðûé 11.05.2012, 17:38
anikaa anikaa âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 19.05.2008
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 7,017
Ñêàçàë(à) ñïàñèáî: 22
Ïîáëàãîäàðèëè 2,827 ðàç(à) çà 2,718 ñîîáùåíèé
anikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåanikaa ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
response-â ëþáîì êîíòåêñòå îçíà÷àåò , ÷òî òå æàëîáû êîòîðûå áûëè-ïðåêðàòèëèñü.

Ôàêò íàñòóïëåíèÿ ðåìèññèè îïðåäåëÿåò âðà÷. Ïî îòñóòñòâèþ ïðèçíàêîâ íàëè÷èÿ áîëåçíè â îðãàíèçìå. Äà, êàêîå-òî âðåìÿ ïîñëå ñïëåíýêòîìèè (åñäè ýòî åäèíñòâåííûé î÷àã) áóäåò ïðîäîëæàòüñÿ ðåìèññèÿ. Êàê äîëãî-íå ïðåäóãàäàòü.
  #29  
Ñòàðûé 11.05.2012, 18:22
srochno srochno âíå ôîðóìà Ïîë ìóæñêîé
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 09.04.2012
Ãîðîä: ...
Ñîîáùåíèé: 61
Ñêàçàë(à) ñïàñèáî: 21
Ïîáëàãîäàðèëè 1 ðàç çà 1 ñîîáùåíèå
srochno *
Åñëè ëèõîðàäêè (òåìïåðàòóðû) óæå íåò, ãåìîãëîáèí ïîâûñèëñÿ, íî êàøåëü îñòàåòñÿ. Ýòî ðåìèññèÿ?

Åñëè ðåìèññèÿ, òî ìîæåò ïðîñòî êóðñ ìàáòåðû ïðèíÿòü?
  #30  
Ñòàðûé 11.05.2012, 18:26
Àâàòàð äëÿ Dr.Vad
Dr.Vad Dr.Vad íà ôîðóìå
Ìîäåðàòîð ôîðóìà ïî ãåìàòîëîãèè
      
 
Ðåãèñòðàöèÿ: 16.01.2003
Ãîðîä: Õüþñòîí, Òåõàñ
Ñîîáùåíèé: 80,648
Ïîáëàãîäàðèëè 33,358 ðàç(à) çà 31,703 ñîîáùåíèé
Dr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåDr.Vad ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
åòî óëó÷øåíèå ñàìî÷óâñòâèÿ â îòâåò íà ïðîâåäåííîå ëå÷åíèå
Öèòàòà:
Ñîîáùåíèå îò anikaa Ïîñìîòðåòü ñîîáùåíèå
Ôàêò íàñòóïëåíèÿ ðåìèññèè îïðåäåëÿåò âðà÷.
__________________
Èñêðåííå,
Âàäèì Âàëåðüåâè÷.
Çàêðûòàÿ òåìà



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 21:15.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.